RESUMO
Adeno-associated viruses (AAV) are well-suited to serve as gene transfer vectors. Onasemnogene abeparvovec uses AAV9 as virus vector. Previous exposure to wild-type AAVs or placental transfer of maternal AAV antibodies, however, can trigger an immune response to the vector virus which may limit the therapeutic effectiveness of gene transfer and impact safety. We present the case of a female patient with spinal muscular atrophy (SMA) and three survival motor neuron 2 (SMN2) gene copies. The infant had elevated titers of AAV9 antibodies at diagnosis at 9 days of age. Being presymptomatic at diagnosis, it was decided to retest the patient's AAV9 antibody titer at two-weekly intervals. Six weeks after initial diagnosis, a titer of 1:12.5 allowed treatment with onasemnogene abeparvovec. The presented case demonstrates that, provided the number of SMN2 gene copies and the absence of symptoms allow, onasemnogene abeparvovec therapy is feasible in patients with initially exclusionary AAV9 antibody titers of >1:50.
Assuntos
Atrofia Muscular Espinal , Placenta , Gravidez , Lactente , Humanos , Feminino , Atrofia Muscular Espinal/genética , Atrofia Muscular Espinal/terapia , Neurônios Motores , Terapia Genética , Vetores Genéticos , Dependovirus/genética , Proteína 2 de Sobrevivência do Neurônio Motor/genéticaRESUMO
Polyglucosan body myopathy-1 (PGBM1) is an extremely rare glycogen storage diseases that leads to muscle weakness and cardiomyopathy due to the accumulation of polyglucosan bodies. The clinical presentation appears to be partially dependent on the genetic mutation, but no clear genotype/phenotype correlation is currently possible. We describe a 7 year old patient, who initially presented with recurrent vomiting and respiratory infections until her first year of life. Diagnostic workup revealed an achalasia and the whole exome sequencing revealed an homozygous RBCK1 (RANBP2-type and C3HC4-type zinc finger containing 1) variant (c.896_899delAGTG) located in exon 7 (mid-domain), which has also been described in 4 patients with PGBM1. The unusual presentation with gastrointestinal and respiratory symptoms before the development of progressive muscle weakness expands the phenotype of this disease.
RESUMO
[This corrects the article DOI: 10.1016/j.ymgmr.2023.101031.].
RESUMO
Newborn screening for 5qSMA offers the potential for early, ideally pre-symptomatic, therapeutic intervention. However, limited data exist on the outcomes of individuals with 4 copies of SMN2, and there is no consensus within the SMA treatment community regarding early treatment initiation in this subgroup. To provide evidence-based insights into disease progression, we performed a retrospective analysis of 268 patients with 4 copies of SMN2 from the SMArtCARE registry in Germany, Austria and Switzerland. Inclusion criteria required comprehensive baseline data and diagnosis outside of newborn screening. Only data prior to initiation of disease-modifying treatment were included. The median age at disease onset was 3.0 years, with a mean of 6.4 years. Significantly, 55% of patients experienced symptoms before the age of 36 months. 3% never learned to sit unaided, a further 13% never gained the ability to walk independently and 33% of ambulatory patients lost this ability during the course of the disease. 43% developed scoliosis, 6.3% required non-invasive ventilation and 1.1% required tube feeding. In conclusion, our study, in line with previous observations, highlights the substantial phenotypic heterogeneity in SMA. Importantly, this study provides novel insights: the median age of disease onset in patients with 4 SMN2 copies typically occurs before school age, and in half of the patients even before the age of three years. These findings support a proactive approach, particularly early treatment initiation, in this subset of SMA patients diagnosed pre-symptomatically. However, it is important to recognize that the register will not include asymptomatic individuals.
Assuntos
Atrofia Muscular Espinal , Proteína 2 de Sobrevivência do Neurônio Motor , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Idade de Início , Áustria/epidemiologia , Progressão da Doença , Alemanha , Atrofia Muscular Espinal/genética , Atrofia Muscular Espinal/diagnóstico , Triagem Neonatal , Sistema de Registros , Estudos Retrospectivos , Proteína 2 de Sobrevivência do Neurônio Motor/genética , SuíçaRESUMO
Overproduction of reactive oxygen species (ROS) is often related to inflammation or cancer and can cause tissue damage. Probes that have been previously reported to image ROS typically rely on imaging techniques that have low depth penetration in tissue, thus limiting their use to superficial disease sites. We report herein a novel formulation of hybrid nanogels loaded with gold nanoparticles (AuNP) to produce contrast for computed tomography (CT) and photoacoustics (PA), both being deep-tissue imaging techniques. The polyphosphazene polymer has been designed to selectively degrade upon ROS exposure, which triggers a switch-off of the PA signal by AuNP disassembly. This ROS-triggered degradation of the nanoprobes leads to a significant decrease in the PA contrast, thus allowing ratiometric ROS imaging by comparing the PA to CT signal. Furthermore, ROS imaging using these nanoprobes was applied to an in vitro model of inflammation, that is, LPS-stimulated macrophages, where ROS-triggered disassembly of the nanoprobe was confirmed via reduction of the PA signal. In summary, these hybrid nanoprobes are a novel responsive imaging agent that have the potential to image ROS overproduction by comparing PA to CT contrast.